Creativity and individuality in matters of hormonal contraception

Authors

DOI:

https://doi.org/10.18370/2309-4117.2016.31.54-59

Keywords:

ethinyl estradiol, dienogest, hormone therapy, prevention, zhastinda

Abstract

The relevance of the discussion about therapeutic and preventive effects of combined oral contraceptives is caused to the fact that their impact is quite often the primary motivation for the appointment and intake the drugs.

“Therapeutic portrait” of the hormonal contraceptive is mainly determined by component of progestin. Knowledge and ability to use the variety of pharmacological effects, metabolic characteristics of progestins and application regimens of combined oral contraceptives allows to achieve the maximum benefit from the appointment of the drug and increases the number of adherents of hormonal contraception among patients and doctors.

The authors reveal the possibility of a creative approach to the appointment of combined oral contraceptives on the example of the combination of 30 mcg of ethinyl estradiol and 2 mg of dienogest, which unites the positive properties of 19-nor progestins and progesterone derivatives. A feature of dienogest is high selectivity for the progesterone receptors, absence of estrogenic, anti-estrogenic and androgenic properties, metabolic neutrality, slight suppression of gonadotropin secretion, pronounced anti-proliferative effect on the endometrium.

This allows to recommend the preparation containing 2 mg of dienogest and 30 mcg of ethinyl estradiol for contraception of conditionally healthy women during the whole reproductive period, without fear to cause hormonal or metabolic disorders, weight gain, decrease of libido. Non-contraceptive benefits of this combination make it preferable for women who suffer from dysmenorrhea, endometriosis, acne, chronic abnormal uterine bleedings.

The decision to choose one or another of drugs is taken individually in each case, taking in attention the severity of clinical manifestations, concomitant somatic and gynecological pathology, previous experience and expectations of patients. However, great importance in the formation of adherence to therapy, particularly in respect of long-term use of schemes, has a price of hormonal contraceptive. The absence of any significant differences in the profiles of the solubility and bioavailability of the generic zhastinda (Alvogen) and original drug allows to reckon them as bioequivalent and makes dienogest in combination with ethinyl estradiol the most available drug for the consumer.

Author Biographies

М. Ю. Сергиенко, Zaporizhzhіa State Medical University

PhD, assistant of the Obstetrics and Gynecology Department

В. Г. Сюсюка, Zaporizhzhіa State Medical University

PhD, associate professor of the Obstetrics and Gynecology Department

Н. Г. Колокот, Zaporizhzhіa State Medical University

Assistant of the Obstetrics and Gynecology Department

References

  1. StatusPraesens. – 2016. – 24 с. Radzinskyi, V.E., Кhamoshina, M.B., Makletsova, S.A. The time of understandable contraception. Optimization of medical choice of hormonal contraception as a way to preserve women’s health at the population level: the newsletter. Moscow. StatusPraesens editorial board (2016): 24 p.
  2. Sedgh, G., Singh, S., Hussain, R. “Intended and unintended pregnancies worldwide in 2012 and recent trends.” Stud Fam Plann 45.3 (2014): 301–14.
  3. Curtis, S., Evens, E., Sambisa, W. “Contraceptive discontinuation and unintended pregnancy: an imperfect relationship.” Int Perspect Sex Reprod Health 37.2 (2011): 58–66.
  4. Hannaford, P.C., Iversen, L., Macfarlane, T.V., et al. “Mortality among contraceptive pill users: cohortevidence from Royal College of General Practitioners’ Oral Contraception Study.” BMJ 340 (2010): 927.
  5. Global Market Research 2014. Available from: [https://www.esomar.org/uploads/public/ publications-store/reports/global-market-research-2014/ ESOMAR-GMR2014_Preview.pdf], last accessed Oct 25, 2016.
  6. Contraception and Health: links of the same chain. Results of the meeting of Russian doctors and representatives of the European Society of Contraception and Reproductive Health (Moscow, March 20, 2012). Moscow. StatusPraesens editorial board (2012): 20 p.
  7. Sergeev, P.V., Shimanovskyi, N.L. “Pharmacological properties of progestogens.” Pharmateca 8 (2003).
  8. Bocker, R., Kleingeist, B. “Der Einflus von Dienogest auf das humane Cytochrome P-450- Enzymsystem in vitro.” In: Dienogest Praklinik und Klinik eines Gestagens Teichmann AT. Ed. by W. de Gruyter. BERLIN 2 Auflage (1995):141–7.
  9. Guengerich, F.P. “Mechanism based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.” Chem Res Toxicol 3 (1990): 363–71.
  10. Hobe, G., Hilltshein, H.G., Kuntzel, B., Klinger, G. “Studies on non-protein bound of dienogest in plasma of different species.” Naunyn-schmiedeber’s Arch Pharmacol 347 (1993) :R44.
  11. Hoffmann, H., Felsch, B., Muller, A., Graser, T. “Safety profile of a fixed formulation containing 2 mg estradiol valerate and 2 mg dienogest (Lafamme) for continuos combined hormone replacement treatment in postmenopausal women.“ Drugs of Today 37(G) (2001): 29–37.
  12. Graser, T., Oettel, M. “Organ targeting with the oral progestin dienogest.” Drugs of Today 32 (Н) (1996): 43–55.
  13. Graser, T., Hoffmann, H., Zimmermann, H., Oettel, M. “Lafamme: A new oral preparation for continuous combined hormone replacement therapy in postmenopausal women.” Drugs of Today 37(G) (2001): 17–27.
  14. Graser, T., Koytchev, R., Romer, T., Georgiev, D.B., et al. “Dienogest as a progestin for hormone replacement therapy.” Drugs of Today 35(C) (1999): 1215–26.
  15. Reznikov, A.G. “Oral contraception.” Medicus Amicus Online 5 (2002). Available from: [http://www.nedug.ru/library/гормональная_ контрацепция/Оральная контрацепция_2#.V3KD_LiLTIU], last accessed Oct 25, 2016.
  16. Gilyazutdinova, Z.Sh., Khasanov, A.A., Egamberdieva, L.D. “Hyperinhibition syndrome of pituitary gonadotropic function.” Kazan Medical Journal 5.87 (2006): 405–7.
  17. Schindler, A.E. “Non-contraceptive benefits of oral hormonal contraceptives.” Reproductive endocrinology 6.14 (2013): 23–30.
  18. Haider, Z., D’Souza, R. “Non-contraceptive benefits and risks of contraception.” Best Pract Res Clin Obstet Gynaecol 23.2 (2009): 249–62. DOI: 10.1016/j.bpobgyn.2008.12.003
  19. Seracchioli, R., Mabrouk, M., Manuzzi, L., et al. “Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis.” Hum Reprod 24.11 (2009): 2729–35. DOI: 10.1093/humrep/dep259
  20. Vercellini, P., Pietropaolo, G., De Giorgi, O., et al. “Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.” Fertil Steril 84(5) (2005): 1375–87. DOI: 10.1016/j.fertnstert.2005.03.083
  21. Vercellini, P., Somigliana, E., Vigano, P., et al. “Endometriosis: current therapies and new pharmacological developments.” Drugs 69.6 (2009): 649–75. DOI: 10.2165/00003495-200969060-00002
  22. Maia, H. Jr., Casoy, J., Correia, T., et al. “Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis.” Gynecol Endocrinol 22.10 (2006):547–51. DOI: 10.1080/09513590601005375
  23. Modugno, F., Ness, R.B., Allen, G.O., et al. “Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.” Am J Obstet Gynecol 191.3 (2004): 733–40. DOI: 10.1016/j.ajog.2004.03.035
  24. Management of patients with endometriosis. Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care, approved by the Order of the Ministry of Health of Ukraine № 319 from 06.04.2016. Reproductive endocrinology 2.28 (2016): 8–20.
  25. Kaminskyi, V.V., Shalko, M.N., Mudra, Y.S. “Original and generic drugs in the field of oral contraceptives.” Reproductive endocrinology 2.28 (2016): 46–9.
  26. Abnormal uterine bleedings. Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care, approved by the Order of the Ministry of Health of Ukraine № 353 from 13.04.2016. Reproductive endocrinology 2.28 (2016): 21–33.
  27. Khamoshina, M.B. “Correction of hyperandrogenic disorders – gynecologists’ practice.” Gynecology Extra Issue (2010).
  28. Medved, M.I., Zhuk, S.I. “The use of ‘off label’ drugs in obstetric and gynecological practice.” Female doctor 1.63 (2016).
  29. “How to understand the tactical approaches to the treatment of breast diseases: clinical overview.” Women’s Health 9.85 (2013): 26–9.
  30. Zhuk, S.I. “Non-contraceptive effects of combined oral contraceptives and ‘contraceptive treatment’.” Female doctor 3.59 (2015): 34–40.
  31. Pirogova, V.I. “Reproductive health of adolescents: social and medical aspects.” Health of Ukraine 4.16 (2014): 8–9.
  32. “Harmony of hormones“ – the confident step into the future.” Conference overview. Health of Ukraine Thematical Issue (2014): 23–5.

Published

2016-10-21

How to Cite

Сергиенко, М. Ю., Сюсюка, В. Г., & Колокот, Н. Г. (2016). Creativity and individuality in matters of hormonal contraception. REPRODUCTIVE ENDOCRINOLOGY, (31), 54–59. https://doi.org/10.18370/2309-4117.2016.31.54-59

Issue

Section

Gynecology

Most read articles by the same author(s)